Academic literature on the topic 'Chronic heart and renal failures'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Chronic heart and renal failures.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Chronic heart and renal failures"
1
El-Belbessi, Sami, Nachman Brautbar, Kenneth Anderson, Vito M. Campese, and Shaul G. Massry. "Effect of Chronic Renal Failure on Heart." American Journal of Nephrology 6, no. 5 (1986): 369–75. http://dx.doi.org/10.1159/000167193.
Full text
2
Parker, J., F. Valle, and D. Cherney. "RENAL OXYGEN CONSUMPTION IN CHRONIC HEART FAILURE." Canadian Journal of Cardiology 34, no. 10 (October 2018): S92—S93. http://dx.doi.org/10.1016/j.cjca.2018.07.478.
Full text
3
Haffner, S. M., K. K. Gruber, G. Aldrete, P. A. Morales, M. P. Stern, and K. R. Tuttle. "Increased lipoprotein(a) concentrations in chronic renal failure." Journal of the American Society of Nephrology 3, no. 5 (November 1992): 1156–62. http://dx.doi.org/10.1681/asn.v351156.
Full textAbstract:
Subjects with chronic renal failure have a greatly increased risk of coronary heart disease and dyslipidemia. Relatively few studies have examined the relationship of chronic renal failure to lipoprotein (Lp)(a) concentrations, an important risk factor for coronary heart disease. Diabetic subjects have been reported to have both increased Lp(a) concentrations and an increased risk of renal failure, thereby possibly confounding the Lp(a)-renal failure association. The association between Lp(a) and chronic renal failure in 359 control subjects and 111 subjects with renal failure was examined. Lp(a) (in milligrams per deciliter) was elevated in subjects with chronic renal failure, regardless of ethnicity (Mexican Americans, 19.8 +/- 2.7 versus 14.1 +/- 1.3; P = 0.03; non-Hispanic white patients, 24.9 +/- 3.0 versus 16.3 +/- 1.2; P = 0.006;). These differences persisted after adjustment for diabetes and ethnicity (P < 0.001). The type of treatment for chronic renal failure (diet, hemodialysis, or peritoneal dialysis) did not have an effect on Lp(a) concentrations. Lp(a) levels were not correlated with the level of creatinine in subjects with chronic renal failure. Thus, the elevation of Lp(a) levels in renal failure must occur early in renal failure, or alternatively, elevated Lp(a) levels may promote progression to chronic renal failure. These results indicate that Lp(a) concentrations are increased in chronic renal failure and may increase the risk for coronary heart disease in these subjects.
4
Boran, Mediha, M. Kamil Göl, Erol Şener, Oğuz Taşdemir, and Kemal Bayazit. "Open Heart Surgery in Patients with Chronic Renal Failure." Asian Cardiovascular and Thoracic Annals 3, no. 3-4 (September 1995): 112–16. http://dx.doi.org/10.1177/021849239500300405.
Full textAbstract:
Coronary and valvular heart diseases are the main causes of mortality and morbidity among the long-term survivors of chronic renal failure. Despite the additional risk factors, open heart surgical procedures have recently been attempted with high rates of success in some patients with chronic renal failure. Forty-three patients with chronic renal failure that have undergone open heart surgery are included in this study. Ten of the patients were female and the mean age was 53.1 ± 11.2 (26 to 71). Twenty-five patients underwent aortocoronary bypass operations and 18 others underwent heart valve replacements. In this group of patients, 38 (88.3%) were in the compensated retention stage of chronic renal failure and 5 (11.7%) were in the end stage. The decompensated chronic renal failure patients were on regular hemodialysis and continued to receive hemodialysis in the preoperative and postoperative period. Sixteen patients of the compensated chronic renal failure group needed hemodialysis postoperatively. Early mortality rate was 7.8% (n = 3). Mean stay in the intensive care unit after the operation was 3.0 ± 3.3 days (2 to 22 days). In the long-term follow-up 3 patients underwent successful renal transplantations within 9 to 18 months after the cardiac operations. Two of these patients had valve replacements and 1 had concomitant valve replacement and coronary artery bypass grafting prior to renal transplantation. We conclude that coronary angiography, catheterization, myocardial revascularization, and valve replacements can be safely performed and should be considered if indicated in chronic renal failure patients.
5
Voronkov, L. G., A. V. Liashenko, N. A. Tkach, and L. P. Paraschenyuk. "Chronic heart failure as multimorbid state." Ukrainian Journal of Cardiology 26, no. 4 (October 8, 2019): 90–101. http://dx.doi.org/10.31928/1608-635x-2019.4.90101.
Full textAbstract:
Regulatory, structural and functional disturbances of other organs and systems (kidney, hepar, vessels, skeletal muscles, brain etc) play the substantial role in CHF. These disturbances may be the conseguences of pre-existing states (hypertension, diabetes, hypo- or hyperthyreoidism etc) and from, other side, may reflect the progressive inherent changes in chronic heart failure (CHF) per se. In particular, currently relevant comorbidities in this syndrome are insulin resistance, diabetes mellitus, renal dysfunction, cognitive impairment, depression peripheral myopathy. Every of them demonstrate the close pathophysiologic interplay with CHF which results in clinical prognosis impairment and in decrease of life quality. Prevalence of renal dysfunction described in 39 % of patients with CHF in our research. Renal dysfunction connected with older age, high class of NYHA, diabetes mellitus, arterial hypertension, higher level of citrulline and uric acid in patients with CHF. Patients with iron deficiency characterized with high class of NYHA, low functionality and poor quality of life. In patients with iron deficiency noted high level of mortality and many critical clinical events. Prevalence of cognitive impairment described in 85 % of patients with CHF in our research. Cognitive dysfunction associated with older age, high class of NYHA, diabetes mellitus, arterial hypertension, bad life quality, high level of ceruloplasmin in patients with CHF. Taking to account above-mentioned comorbidities in quideline-recommended management of CHF and the use of additional therapeutic approaches targeted to its treatment represent the contemporary strategy of personalized treatment in this syndrome.
6
Курлянская, Е. К. "Renal Denervation in Patients with Chronic Heart Failure." Кардиология в Беларуси, no. 4 (September 26, 2022): 456–68. http://dx.doi.org/10.34883/pi.2022.14.4.008.
Full textAbstract:
Цель. Проанализировать отдаленные результаты денервации почечных артерий у пациентов с хронической сердечной недостаточностью (ХСН).Материалы и методы. В исследование включен 61 пациент с ХСН III–IV ФК по NYHA, которому выполнена катетерная абляция симпатических нервов почечных артерий. До поступления в стационар и в клинике пациенты находились на оптимальной медикаментозной терапии в соответствии с рекомендациями и протоколами по ведению пациентов с ХСН. Оценка клинико-анамнестических, инструментально-диагностических и лабораторных параметров выполнялась до ДПА, а также через 6 и 12 месяцев после абляции. Респондерами ДПА считали пациентов с уменьшением КСО по данным ЭхоКГ на 15% и более относительно значений до выполнения ДПА. Через 12 месяцев после ДПА были сформированы 2 группы: группа 1 – респондеры ДПА (39 пациентов), группа 2 – нереспондеры ДПА (22 пациента). Номинальные данные представлены в виде абсолютной (n) и относительной частот (доля, выраженная в %), количественные данные – в виде медианы (Me) и межквартильного диапазона (LQ; UQ).Результаты. У пациентов с ХСН ФК III–IV положительный эхокардиографический ответ на ДПА сопровождался значимым увеличением ФВ ЛЖ (р=0,008), снижением ИЛС (р=0,035), среднего показателя продольной деформации миокарда ЛЖ (р=0,012), ДЛА (р=0,018), концентрации в крови NT-proBNP (р=0,017), тканевого ингибитора ММП (р=0,028) и СРБ (р=0,028), а также уменьшением суточного количества групповых ЖЭС (р=0,048). Независимо от эхокардиографического ответа на интервенционное лечение качество жизни и результаты теста 6-минутной ходьбы в течение 6 месяцев улучшились у всех пациентов, но через 12 месяцев у респондеров ДПА количество баллов по Миннесотскому опроснику было меньше (р=0,046), а пройденная за 6 минут дистанция – больше (р=0,048), чем у нереспондеров ДПА. Эхокардиографический эффект ДПА у пациентов с ХСН связан с исходным суточным количеством групповых желудочковых экстрасистол (р=0,048), концентрацией в крови ST2 (р=0,020) и ТИММП (р=0,020).Выводы. Катетерная ДПА у пациентов с ХСН ФК III–IV способствует улучшению внутрисердечной гемодинамики, снижению суточного количества ЖЭС и снижению уровня лабораторных маркеров, ассоциированных с фиброзом миокарда. Обратное ремоделирование ЛЖ в течение 12 месяцев после ДПА ассоциировано с суточным количеством желудочковых экстрасистол, концентрацией в крови ST2 и ТИММП до интервенционного вмешательства. Purpose. To analyze long-term results of renal denervation (RND) in patients with chronic heart failure.Materials and methods. The study enrolled 61 patients with chronic heart failure class III–IV according to NYHA who underwent catheter ablation of the sympathetic nerves of the renal arteries. Before admission and during their in-patient stay, the patients were on optimal drug therapy in line with the recommendations and protocols for CHF management. Evaluation of clinical and anamnestic, instrumental, diagnostic and laboratory parameters was performed before RND, as well as 6 and 12 months after ablation. The patients with 15% or more reduction of ESV according to Echo compared with the parameters before cardiac output were considered as responders. Two groups were formed 12 months after RND: group 1 – RND responders (39 patients), group 2 – nonresponders (22 patients). Nominal data are presented as absolute (n) and relative frequencies (fraction in percentage terms), quantitative data as median (Me) and interquartile range (LQ; UQ).Results. The positive echocardiographic response to RND in patients with CHF class III–IV was accompanied by a significant increase in LV EF (p=0.008), decrease in WMSI (p=0.035), mean LV myocardial longitudinal strain (p=0.012), pulmonary arterial pressure (p=0.018), NT-proBNP concentration (p=0.017), TIMP (p=0.028) and CRP (p=0.028), and a decrease in daily group VPB (p=0.048). Regardless of the echocardiographic response to interventional treatment, quality of life and 6-minute walk test scores improved at 6 months in all patients, but at 12 months, responders to the RND had a lower Minnesota Questionnaire score (p=0.046) and a greater distance walked in 6 minutes (p=0.048) than nonresponders to the RND. The echocardiographic effect of RND in patients with CHF was associated with baseline daily number of group ventricular premature beats (p=0.048), ST2 concentration in blood (p=0.020), and TIMP (p=0.020).Conclusions. Catheter RND in patients with CHF class III–IV improves intracardiac hemodynamics, reduces the daily number of VPB and decreases the level of laboratory markers associated with myocardial fibrosis. Reversible LV remodeling within 12 months after RND was associated with the daily number of ventricular premature beats, ST2 concentration in blood, and TIMP prior to interventional treatment.
7
van der Meer, P., and D. J. van Veldhuisen. "Anaemia and renal dysfunction in chronic heart failure." Heart 95, no. 21 (October 14, 2009): 1808–12. http://dx.doi.org/10.1136/hrt.2008.151258.
Full text
8
Waldum, Bård, Arne S. Westheim, Leiv Sandvik, Berit Flønæs, Morten Grundtvig, Lars Gullestad, Torstein Hole, and Ingrid Os. "Renal Function in Outpatients With Chronic Heart Failure." Journal of Cardiac Failure 16, no. 5 (May 2010): 374–80. http://dx.doi.org/10.1016/j.cardfail.2010.01.001.
Full text
9
Omar, Sabry, and Ahmed Zedan. "Cardiorenal syndrome." Southwest Respiratory and Critical Care Chronicles 1, no. 1 (January 30, 2013): 11. http://dx.doi.org/10.12746/swrccc.v1i1.24.
Full textAbstract:
Cardiovascular disease is the leading cause of death in patients with chronic kidney disease. Heart failure may lead to acute kidney injury and vice versa. Chronic kidney disease may affect the clinical outcomes in patients with cardiovascular disorders. Renal impairment with any degree of albuminuria has been increasingly recognized as an independent risk factor for cardiovascular events and heart failure hospitalizations, while chronic heart failure may cause chronic kidney disease. The bidirectional nature of these disorders contributes to the complexity and the composite definitions of cardiorenal syndromes. However, the most important clinical trials in heart failure tend to exclude patients with significant renal dysfunction. The mechanisms whereby renal insufficiency worsens the outcome in heart failure are not known, and several pathways could contribute to the ‘‘vicious heart/kidney circle.’’ Traditionally, renal impairment has been attributed to the renal hypoperfusion due to reduced cardiac output and decreased systemic pressure. The hypovolemia leads to sympathetic activity, increased renin-angiotensin aldosterone pathway, and arginine-vasopressin release. These mechanisms cause fluid and sodium retention, peripheral vasoconstriction, and volume overload. Therapy to improve renal dysfunction, reduce neurohormonal activation and ameliorate renal blood flow could lead to a reduction in mortality and hospitalization in patients with cardiorenal syndrome.
10
Unic-Stojanovic, Dragana, Miroslav Milicic, Petar Vukovic, Srdjan Babic, and Miomir Jovic. "Heart surgery in patients on chronic dialysis." Medical review 66, no. 1-2 (2013): 64–69. http://dx.doi.org/10.2298/mpns1302064u.
Full textAbstract:
Introduction. Patients on dialysis for end-stage renal failure are subjected to cardiac surgery with increasing frequency. End-stage renal failure is known to be an important risk factor for complications of cardiac operations performed with cardiopulmonary bypass. The aim of this study was to determine the impact of preoperative clinical status and operative variables on perioperative morbidity and mortality in hemodialysis dependent patients subjected to a cardiac surgery. Material and Methods. The following operative variables were examined: urgency, type and duration of surgery and duration of extracorporeal circulation. The study is a retrospective analysis of consecutive patients with end-stage renal failure dependent on maintenance hemodialysis who underwent cardiac surgery during four years. Results. The study included 46 patients. Operations performed included isolated coronary artery bypass grafting (CABG, n = 24), valve surgery alone (n = 6), and combined valve surgery or coronary artery bypass grafting and valve surgery (n = 16). The perioperative mortality rate was 13% with four fatal outcomes in patients who had undergone combined cardiac surgery. We found age > 70 years, preoperative New York Heart Association class IV, preoperative anemia, combined surgery and emergent surgery to be associated with a higher relative risk for perioperative death. Conclusion. Patients on dialysis have an increased morbidity and mortality following cardiac surgery; however, we believe that end-stage renal failure should not be regarded as a contraindication to cardiac surgery or cardiopulmonary bypass.
Dissertations / Theses on the topic "Chronic heart and renal failures"
1
He, Jiang, Michael Shlipak, Amanda Anderson, Jason A. Roy, Harold I. Feldman, Radhakrishna Reddy Kallem, Radhika Kanthety, et al. "Risk Factors for Heart Failure in Patients With Chronic Kidney Disease: The CRIC (Chronic Renal Insufficiency Cohort) Study." WILEY, 2017. http://hdl.handle.net/10150/625054.
Full textAbstract:
Background-Heart failure is common in patients with chronic kidney disease. We studied risk factors for incident heart failure among 3557 participants in the CRIC (Chronic Renal Insufficiency Cohort) Study. Methods and Results-Kidney function was assessed by estimated glomerular filtration rate (eGFR) using serum creatinine, cystatin C, or both, and 24-hour urine albumin excretion. During an average of 6.3 years of follow-up, 452 participants developed incident heart failure. After adjustment for age, sex, race, and clinical site, hazard ratio (95% CI) for heart failure associated with 1 SD lower creatinine-based eGFR was 1.67 (1.49, 1.89), 1 SD lower cystatin C-based-eGFR was 2.43 (2.10, 2.80), and 1 SD higher log-albuminuria was 1.65 (1.53, 1.78), all P< 0.001. When all 3 kidney function measures were simultaneously included in the model, lower cystatin C-based eGFR and higher log-albuminuria remained significantly and directly associated with incidence of heart failure. After adjusting for eGFR, albuminuria, and other traditional cardiovascular risk factors, anemia (1.37, 95% CI 1.09, 1.72, P= 0.006), insulin resistance (1.16, 95% CI 1.04, 1.28, P= 0.006), hemoglobin A1c (1.27, 95% CI 1.14, 1.41, P< 0.001), interleukin-6 (1.15, 95% CI 1.05, 1.25, P= 0.002), and tumor necrosis factor-a (1.10, 95% CI 1.00, 1.21, P= 0.05) were all significantly and directly associated with incidence of heart failure. Conclusions-Our study indicates that cystatin C-based eGFR and albuminuria are better predictors for risk of heart failure compared to creatinine-based eGFR. Furthermore, anemia, insulin resistance, inflammation, and poor glycemic control are independent risk factors for the development of heart failure among patients with chronic kidney disease.
2
Brunini, Tatiana Marlowe Cunha. "L-arginine-nitric oxide pathway in blood cells from chronic renal and heart failure patients." Thesis, University of Oxford, 2000. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.326115.
Full text
3
Mark, Patrick Barry. "Redefinition of uraemic cardiomyopathy with cardiac magnetic resonance imaging." Thesis, Connect to e-thesis, 2008. http://theses.gla.ac.uk/65/.
Full textAbstract:
Thesis (Ph.D.) - University of Glasgow, 2008.Ph.D. thesis submitted to the Faculty of Medicine, Division of Cardiovascular and Medical Sciences, University of Glasgow, 2007. Includes bibliographical references. Print version also available.
4
Coles, Andrew H. "Long-Term Survival and Prognostic Factors in Patients with Acute Decompensated Heart Failure According to Ejection Fraction Findings: A Population-Based Perspective: A Master Thesis." eScholarship@UMMS, 2014. https://escholarship.umassmed.edu/gsbs_diss/722.
Full textAbstract:
Limited data exists describing the long-term prognosis of patients with acute decompensated heart failure (ADHF) further stratified according to currently recommended ejection fraction (EF) findings. In addition, little is known about the magnitude of, and factors associated with, long-term prognosis for these patients. Based on previously validated and clinically relevant criteria, we defined HF-REF as patients with an EF value ≤40%, HF-PEF was defined as an EF value > 50%, and HF-BREF was defined as patients with an EF value during their index hospitalization between 41 and 49%. The hospital medical records of residents of the Worcester (MA) metropolitan area who were discharged after ADHF from all 11 medical centers in central Massachusetts during the 5 study years of 1995, 2000, 2002, 2004, and 2006 were reviewed. Follow-up was completed through 2011 for all patient cohorts. The average age of this population was 75 years, the majority was white, and 44% were men. Patients with HF-PEF experienced higher post discharge survival rates than patients with either HF-REF or HF-BREF at 1, 2, and 5-years after discharge. Advanced age and lower estimated glomerular filtration rate findings at the time of hospital admission were important predictors of 1-year death rates, irrespective of EF findings. Previously diagnosed chronic obstructive pulmonary disease, chronic kidney disease, and atrial fibrillation were associated with a poor prognosis in patients with PEF and REF whereas a history of diabetes was an important prognostic factor for patients with REF and BREF. In conclusion, although improvements in 1-year post-discharge survival were observed for patients in each of the 3 EF groups examined to varying degrees, the post- 7 discharge prognosis of all patients with ADHF remains guarded. In addition, we observed differences in several prognostic factors between patients with ADHF with varying EF findings, which have implications for more refined treatment and surveillance plans for these patients.
5
Coles, Andrew H. "Long-Term Survival and Prognostic Factors in Patients with Acute Decompensated Heart Failure According to Ejection Fraction Findings: A Population-Based Perspective: A Master Thesis." eScholarship@UMMS, 2008. http://escholarship.umassmed.edu/gsbs_diss/722.
Full textAbstract:
Limited data exists describing the long-term prognosis of patients with acute decompensated heart failure (ADHF) further stratified according to currently recommended ejection fraction (EF) findings. In addition, little is known about the magnitude of, and factors associated with, long-term prognosis for these patients. Based on previously validated and clinically relevant criteria, we defined HF-REF as patients with an EF value ≤40%, HF-PEF was defined as an EF value > 50%, and HF-BREF was defined as patients with an EF value during their index hospitalization between 41 and 49%. The hospital medical records of residents of the Worcester (MA) metropolitan area who were discharged after ADHF from all 11 medical centers in central Massachusetts during the 5 study years of 1995, 2000, 2002, 2004, and 2006 were reviewed. Follow-up was completed through 2011 for all patient cohorts. The average age of this population was 75 years, the majority was white, and 44% were men. Patients with HF-PEF experienced higher post discharge survival rates than patients with either HF-REF or HF-BREF at 1, 2, and 5-years after discharge. Advanced age and lower estimated glomerular filtration rate findings at the time of hospital admission were important predictors of 1-year death rates, irrespective of EF findings. Previously diagnosed chronic obstructive pulmonary disease, chronic kidney disease, and atrial fibrillation were associated with a poor prognosis in patients with PEF and REF whereas a history of diabetes was an important prognostic factor for patients with REF and BREF. In conclusion, although improvements in 1-year post-discharge survival were observed for patients in each of the 3 EF groups examined to varying degrees, the post- 7 discharge prognosis of all patients with ADHF remains guarded. In addition, we observed differences in several prognostic factors between patients with ADHF with varying EF findings, which have implications for more refined treatment and surveillance plans for these patients.
6
Galil, Arise Garcia de Siqueira. "Prevalência de anemia e doença renal crônica em portadores de insuficiência cardíaca sistólica num ambulatório de hipertensos e diabéticos." Universidade Federal de Juiz de Fora (UFJF), 2008. https://repositorio.ufjf.br/jspui/handle/ufjf/2837.
Full textAbstract:
Submitted by Renata Lopes (renatasil82@gmail.com) on 2016-10-13T18:19:07Z
No. of bitstreams: 1
arisegarciadesiqueiragalil.pdf: 700408 bytes, checksum: bda59712c26407e09b49f3dd136c52b2 (MD5)Approved for entry into archive by Adriana Oliveira (adriana.oliveira@ufjf.edu.br) on 2016-10-22T13:00:41Z (GMT) No. of bitstreams: 1 arisegarciadesiqueiragalil.pdf: 700408 bytes, checksum: bda59712c26407e09b49f3dd136c52b2 (MD5)
Made available in DSpace on 2016-10-22T13:00:41Z (GMT). No. of bitstreams: 1 arisegarciadesiqueiragalil.pdf: 700408 bytes, checksum: bda59712c26407e09b49f3dd136c52b2 (MD5) Previous issue date: 2008-02-15
Introdução: A insuficiência cardíaca (IC) tem alta morbimortalidade que decorre de fatores causais e refratariedade ao tratamento. A doença renal crônica (DRC) e a anemia têm se associado a pior prognóstico em pacientes com IC grave, especialmente os hospitalizados. Há, porém, poucos estudos que avaliem a prevalência e as conseqüências da DRC e da anemia em pacientes com IC acompanhados ambulatorialmente. Objetivos: Avaliar a prevalência da DRC e anemia e o impacto de desfechos cardiovasculares em portadores de IC sistólica estágios B e C. Pacientes e Métodos: Foram estudados pacientes adultos, com idade >18 anos e diagnóstico de IC sistólica e com fração de ejeção (EF) ≤45%, selecionados do ambulatório do Serviço de Hipertensão, Diabetes e Obesidade do SUS de Juiz de Fora e acompanhados por 12 meses. A anemia foi definida como hemoglobina <12,0g/dl nas mulheres e <13,0g/dl nos homens. A reserva de ferro foi considerada adequada quando índice de saturação da transferrina encontrava-se ≥20% e a ferritina ≥100ηg/dl. A filtração glomerular foi estimada pela fórmula do estudo MDRD e a DRC foi definida como proposto pelo K/DOQI da National Kidney Foundation americana. Considerou-se com desfechos cardiovasculares (CV) a ocorrência de hospitalização e/ou morte decorrente da IC. Os dados demográficos, de exame físico e laboratorial foram obtidos do prontuário dos pacientes. Resultados: Foram avaliados 83 pacientes, com idade média de 62,7±12 anos, sendo 56,6% do sexo feminino. A média da fração de ejeção (FE) foi de 37,8+7,9% e a maioria dos indivíduos (60,2%) estava no estágio C. A prevalência de anemia foi de 24,09%; 30,30% no estágio B e 20% no estágio C. A prevalência de DRC foi elevada, presente em 49,4% da amostra, 42,4% no estágio B da IC e 54% no estágio C. Todos os pacientes com anemia tinham reserva de ferro normal e 68,6% apresentavam DRC concomitante. Os desfechos CV ocorreram em 26,5% da amostra. Na estratificação dos pacientes nos estágios B e C da IC e presença ou não de DRC, evidenciou que 100% e 64,7% apresentaram desfechos, respectivamente. Na análise multivariada, após ajustes para fatores prognósticos no período basal, o diagnóstico de DRC aumentou em 3,6 vezes a possibilidade de desfechos (IC 95%1,04-12,67, p=0,04), enquanto os níveis mais elevados de sódio sérico (R 0,807, IC95%0,862-0,992, p=0,03) e da fração de ejeção (R 0,925, IC95% 0,862-0,942, p= 0,03) se mostraram protetores. Conclusão: Na coorte de pacientes estudada, composta de pacientes com IC estágios B e C, a ocorrência de anemia foi compatível com a observada em outros estudos e com tendência de se associar com menor filtração glomerular. A DRC foi prevalente e independentemente se associou a maior risco de hospitalizações e mortes secundárias à descompensação cardíaca, especialmente nos pacientes assintomáticos.
Introduction: Chronic heart failure (CHF) has a high morbidity and mortality which are consequent to etiologic factors and no response to treatment. Anemia and chronic kidney disease (CKD) have been associated to worse outcome in patients with severe hospitalized CHF. So far, there is few studies that assessed the prevalence and the consequences of anemia and CKD in outpatients with CHF. Aim: To study the prevalence of CKD and anemia and the impact of CV end points in patients with systolic CHF followed in an outpatient clinic. Methods: This is prospective cohort study, dealing with adult patients older than 18 years of age and diagnosis of systolic CHF and ejection fraction (EF) ≤45%, selected from the Hypertension, Diabetes and Obesity Outpatient Clinic of SUS of Juiz de Fora. Anemia was defined as hemoglobin <12,0g/dL in women and <13g/dL in men and women after the menopause. Normal iron store was defined when transferring saturation index was >20% and/or ferritin >100ηg/dL. The glomerular filtration rate was estimated from serum creatinine usinf the MDRD study formula, and CKD was defined as suggested by the K/DOQI of National Kidney Foundation. CV endpoints were defined as death or hospitalization due to CHF, in 12 months follow up. Demographic and clinical date were obtained from the patients’ charts. Results: Eight three patients were studied, the mean age was 62.7±12 years, and 56.6% were female. The EF was 37,8+7,9%, and the majority of the patients had stage C CHF (60,2%). The prevalence of anemia was 24,1%; 30,3% in stage B and 50% in stage C. CKD was diagnosed in 49.4% of the patients, 42,4% of the stage B and 54% in the stage C. All patients with anemia had normal iron storage, and 68,6% had concomitant CKD. Cardiovascular endpoints were observed in 26.5% of the patients. When the sample was stratified in stages B and C of CHF and presence or absence of CKD, it was found that 100% and 64.7% had CV endpoints, respectively. After adjustments for all other prognostic factors at baseline, it was observed that the diagnosis of CKD increased in 3.6 folds the hazard of CV endpoints (CI 95% 1,04-12,67, p=0,04), whereas higher ejection fraction (R 0,925, IC 95% 0,862-0,942, p= 0,03) and serum sodium (R 0,807, IC 95% 0,862-0,992, p=0,03) were protectors. Conclusion: In this cohort of outpatients with CHF stages B and C, the occurrence of anemia was low and frequently associated with concomitant CKD. On the other hand, CKD was prevalent and independently associated with heightened risk for hospitalization and death secondary of cardiovascular causes, mainly in asymptomatic patients.
7
Gatti, Márcio. "Variabilidade da freqüência cardíaca e seu valor prognóstico imediato em nefropatas crônicos submetidos à hemodiálise." Faculdade de Medicina de São José do Rio Preto, 2015. http://hdl.handle.net/tede/402.
Full textAbstract:
Submitted by Fabíola Silva (fabiola.silva@famerp.br) on 2018-02-27T14:13:48Z
No. of bitstreams: 1
marciogatti_dissert.pdf: 2240052 bytes, checksum: 38cfe0f95ee7d8c6d51f09ffe75f33ba (MD5)Made available in DSpace on 2018-02-27T14:13:48Z (GMT). No. of bitstreams: 1 marciogatti_dissert.pdf: 2240052 bytes, checksum: 38cfe0f95ee7d8c6d51f09ffe75f33ba (MD5) Previous issue date: 2015-11-17
Introduction: Chronic Renal Failure (CRF) is a metabolic syndrome resulting in progressive loss of ability to renal excretion. In advanced stages dialysis is necessary. The introduction of new technological advances in hemodialysis made this procedure safe and able to maintain patients' lives for long periods. However, in 30% of the hemodialysis, may occur some kind of complication. The heart rate variability (HRV) reveals information on the functional state of the autonomic nervous system and reflects the balance between the sympathetic and parasympathetic branches of the same. HRV analysis have been proposed as a component of the clinical evaluation for risk stratification of patients. HRV can be studied by linear methods, time domain and frequency and nonlinear methods in the field of chaos. Objective: Assess whether or not there is an association between lower HRV immediately preceding the hemodialysis and the occurrence of complications during or after the same period. Casuistic and Method: 44 unselected patients were included in the study, regardless of sex and age being 15 (34.1%) were female and 29 patients (65.9%) males, with 61.7 ± 14.5 years. Inclusion criteria were considered just the fact of having IRC, be in regular program of performing hemodialysis in the dialysis unit at Hospital de Base (HB) of São José do Rio Preto. The methodology consisted of the assessment of HRV in the time, frequency and chaos, using registration electrocardiographic time series with the aid of equipment Polar RS800CX for 20 minutes moments before initiating hemodialysis session. The 44 patients were followed throughout the dialysis period by verifying the occurrence of complications. Results: 35 patients (NC) had no complications during hemodialysis, while 9 patients (C) had complications, such as hypotension, hypoglycemia, and cramps. The results showed no association between lower HRV with the occurrence of complications during or after hemodialysis. But it was evident that the diabetic patients had a higher probability of complications, because it was the only variable that showed a statistically significant difference. Comparing the results of HRV in diabetic patients with nondiabetic patients, we found lower values for the variables that represent the sympathetic autonomic activity, such as SDNN, LF, SD2 and alpha 1. Conclusions: HRV in the time, frequency and chaos was not characterized as a predictor of the occurrence of complications during or after hemodialysis. However, in diabetic patients there is a significant reduction in the sympathetic component associated with the occurrence of complications, highlighting the possibility of using a simple, noninvasive method for determining prognosis by studying HRV.
Introdução: Insuficiência Renal Crônica (IRC) é uma síndrome metabólica decorrente de perda progressiva da capacidade de excreção renal. Em fases avançadas é necessário o tratamento dialítico. A introdução de novos avanços tecnológicos no tratamento hemodialítico tornou esse procedimento seguro e capaz de manter a vida dos pacientes por longos períodos. Entretanto, em 30% das sessões de hemodiálise, pode ocorrer algum tipo de complicação. A variabilidade da freqüência cardíaca (VFC) revela informações do estado funcional do sistema nervoso autônomo e reflete o balanço entre os ramos parassimpático e simpático do mesmo. Análises da VFC têm sido propostas como um componente da avaliação clínica para a estratificação do risco dos pacientes. A VFC pode ser estudada por meio de métodos lineares, no domínio do tempo e da frequência e métodos não lineares, no domínio do caos. Objetivo: Avaliar se há ou não associação entre menor VFC no período imediatamente precedente à realização de hemodiálise e a ocorrência de complicações durante ou logo após a mesma. Casuística e Método: Foram incluídos no estudo 44 pacientes não selecionados, independente do sexo e idade sendo 15 (34,1%) do sexo feminino e 29 (65,9%) do sexo masculino, com 61,7±14,5 anos. Os critérios de inclusão foram considerados apenas o fato de ser portador de IRC, estar em programa regular de realização de hemodiálise na Unidade de Terapia Dialítica do HB de São José do Rio Preto. A metodologia consistiu na avaliação da VFC nos domínios do tempo, frequência e caos, utilizando-se de registro de series temporais eletrocardiográficas com auxilio do equipamento Polar RS800CX, por 20 minutos instantes antes de iniciarem a sessão de hemodiálise. Os 44 pacientes foram acompanhados durante todo o período dialítico com a verificação da ocorrência de complicações. Resultados: 35 pacientes (NC) não tiveram complicações durante a hemodiálise, enquanto que 9 pacientes (C) apresentaram complicações, como hipotensão, hipoglicemia e câimbras. Os resultados obtidos mostraram que não houve associação entre uma menor VFC com a ocorrência de complicações durante ou logo após a hemodiálise. Porém foi evidente que os pacientes diabéticos apresentaram maior probabilidade de complicações, pois foi a única variável que apresentou diferença estatisticamente significativa. Comparando os resultados da VFC nos pacientes diabéticos com os não diabéticos, encontramos menores valores para as variáveis que representam a atividade autonômica simpática, como SDNN, LF, SD2 e alfa 1. Conclusões: A VFC nos domínios do tempo, freqüência e caos não se caracterizou como preditivo da ocorrência de complicações durante ou logo após a hemodiálise. Entretanto, em pacientes diabéticos há uma redução significante do componente simpático associado à ocorrência de complicações, ressaltando-se a possibilidade de utilização de um método simples e não invasivo para determinação de prognóstico por meio do estudo da VFC.
8
Ardito, Sabrina Queiroz. "Impacto da Insuficiência renal crônica associada à insuficiência Cardíaca Crônica Sistólica em pacientes com Cardiomiopatia Chagásica: Prevalência e Prognóstico." Faculdade de Medicina de São José do Rio Preto, 2011. http://bdtd.famerp.br/handle/tede/116.
Full textAbstract:
Made available in DSpace on 2016-01-26T12:51:32Z (GMT). No. of bitstreams: 1
sabrinaqueirozardito_dissert.pdf: 404181 bytes, checksum: cc58335cbd6ac86952c065cd2a36213e (MD5)
Previous issue date: 2011-12-16This study aimed at determining the prevalence and the prognostic significance of chronic renal impairment in patients with chronic systolic heart failure secondary to Chagas cardiomyopathy. A total of 245 patients followed at the Cardiomyopathy Outpatient service from January, 2000 to December, 2008 with the diagnosis of chronic systolic heart failure secondary to Chagas cardiomyopathy were included. Chronic renal impairment was diagnosed in 42 (17%) patients. A Cox proportional hazards model was used to evaluate the role of chronic renal impairment as a prognostic index, and a Kaplan-Meier survival curve to study its association with all-cause mortality. Baseline characteristics of patients with and without chronic renal impairment were similar. Beta-Blocker therapy (Hazard ratio=0,42; 95% Confidence Interval 0,27 to 0,63, p value <0,005), left ventricular ejection fraction (Hazard Ratio=0,97; 95% Confidence Interval 0,95 to 0,99; p value=0,005), serum sodium levels (Hazard ratio=0,94; 95% Confidence Interval 0,90 to 0,98; p value=0,004), inotropic support (Hazard Ratio= 1,85; 95% Confidence Interval 1,21 to 2,64; p value= 0,03), and digoxin use (Hazard ratio=2,35; 95% Confidence Interval 1,15 to 4,81; p value=0,02) were independent predictors of all- cause mortality. Survival probability at 12, 24, 36, and 60 months was 74%, 60%, 52%, and 37%, respectively, in patients with chronic renal impairment, and 84%, 70%, 70%, and 35% ,respectively, in patients without (p>0,05). Chronic renal impairment has a low prevalence and no prognostic significance in patients with chronic systolic heart failure secondary to Chagas Cardiomyopathy.
Este estudo tem por objetivo determinar a prevalência e a significância prognóstica da disfunção renal crônica em pacientes com insuficiência cardíaca crônica sistólica secundária à cardiomiopatia chagásica. Duzentos e quarenta e cinco pacientes seguidos no Ambulatório de Cardiomiopatia de Janeiro de 2000 a Dezembro de 2008 com o diagnóstico de insuficiência cardíaca crônica secundária a cardiomiopatia Chagásica foram incluídos no estudo. Disfunção renal crônica foi diagnósticada em 42 (17%) pacientes. Um modelo proporcional de Cox foi usado para avaliar a evolução da disfunção renal crônica como um indice prognóstico, e uma curva de sobrevida de Kaplan-Meier para estudar sua associação com todas as causas de mortalidade. As características basais dos pacientes com e sem disfunção renal crônica foram semelhantes. Terapia com betabloqueador (Razão de Risco=0,42; Intervalo de Confiança 95% de 0,27 a 0,63, p<0,005)], fração de ejeção ventricular esquerda(Razão de Risco=0,97; Intervalo de Confiança 95% de 0,95 a 0,99; p=0,005), nível sérico de sódio(Razão de Risco=0,94; Intervalo de Confiança 95% de 0,90 a 0,98; p=0,004), suporte inotrópico(Razão de risco = 1,85; Intervalo de Confiança 95% de 1,21 a 2,64; p= 0,03) e uso de digoxina(Razão de Risco =2,35; Intervalo de Confiança 95% de 1,15 a 4,81; p=0,02) foram fatores de predição independentes de mortalidade geral. A probabilidade de sobrevida em 12, 24, 36, e 60 meses foi 74%, 60%, 52%, e 37%, respectivamente, em pacientes com disfunção renal crônica e 84%, 70%, 70% e 35%, respectivamente, em pacientes sem disfunção renal crônica(p>0,05). A disfunção renal crônica tem baixa prevalência e não tem significância prognóstica em pacientes com insuficiência cardíaca crônica sistólica secundária a cardiomiopatia chagásica.
9
Bosco-Lévy, Pauline. "Heart failure in France : chronic heart failure therapeutic management and risk of cardiac decompensation in real-life setting." Thesis, Bordeaux, 2019. http://www.theses.fr/2019BORD0348.
Full textAbstract:
En France, environ un million de personnes seraient touchées par l’insuffisance cardiaque (IC) ; on recense près de 70 000 décès liés à l’IC, et plus de 150 000 hospitalisations et cela, malgré une prise en charge thérapeutique bien codifiée. Ces chiffres devraient s’accroitre dans les années futures du fait notamment du vieillissement de la population.L’objectif de ce travail était d’étudier l’utilisation des traitements pharmacologiques indiqués dans le traitement de l’IC (beta bloquant, inhibiteur de l’enzyme de conversion, anti-aldostérone, antagoniste des récepteurs à l’angiotensine II, diurétiques, digoxine, ivabradine) en situation réelle de soin, et d’identifier les facteurs cliniques ou pharmacologiques associés à la survenue d’un épisode de décompensation cardiaque.Un premier travail a permis de mesurer la fiabilité des bases de données médico-administratives françaises pour identifier des patients IC.Une deuxième étude a permis d’estimer que 17 à 37% de patients IC n’étaient exposés à aucun traitement de l’IC dans l’année suivant une première hospitalisation pour IC.Les troisième et quatrième parties de cette thèse ont mis en évidence qu’environ un quart des patients IC étaient réhospitalisés dans les 2 ans suivant une première hospitalisation. Les principaux facteurs cliniques prédictifs de cette réhospitalisation étaient l’âge, l’hypertension artérielle, la fibrillation auriculaire et le diabète. L’association retrouvée entre l’utilisation de fer bivalent et la réhospitalisation pour IC, souligne l’importance du risque lié à la présence d’une anémie ou d’une déficience en fer dans la survenue d’un épisode de décompensation cardiaque.Ces résultats permettent de reconsidérer la prise en charge thérapeutique chez les patients IC et mettent en avant la nécessité de renforcer la surveillance des patients les plus à risque de décompenser leur ICIn France, around one million persons would be affected by heart failure (HF); there are nearly 70 000 deaths related to HF and more than 150 000 hospitalizations despite a well defined treatment management. These numbers should increase in the next years due in particular to the ageing of the population.The objective of this work was to study the use of the pharmacological treatments indicated in HF (beta-blocker, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, aldosterone antagonist, diuretics, digoxin, ivabradine) in real-world setting and to identify the clinical or pharmacological predictors associated with a new episode of cardiac decompensation.A first work has enabled to estimate the accuracy of French claims databases in identifying HF patients.A second study estimated that 17 to 37% HF patients were not exposed to any HF treatment in the year following an incident HF hospitalization.The third and fourth parts of this thesis showed that almost one forth of HF patients was rehospitalized within the 2 years following a first hospitalization. The main clinical predictors of rehospitalization were age, high blood pressure, atrial fibrillation and diabetes. The association found between bivalent iron use and HF rehospitalization underlines the importance of the risk related to anemia or iron deficiency in the occurrence of a cardiac exacerbation episode.These results allow to reconsider the treatment management of HF patients and highlight the need to reinforce the surveillance of patients with a highest risk of cardiac exacerbation
10
Mebrate, Yoseph. "Mathematical modelling of periodic breathing in chronic heart failure to design novel real-time dynamic therapy." Thesis, Imperial College London, 2014. http://hdl.handle.net/10044/1/51091.
Full textAbstract:
Periodic breathing (PB) is common in chronic heart failure (CHF) and has poor prognosis. The most commonly used therapy option involve continuous positive airway pressure, which is not acceptable to all patients. In this thesis I present a mathematical model providing a novel approach to treat PB with carefully controlled dynamic administration of supplementary CO2. I explored the consequences of phasic CO2 administration, with different timing and dosing algorithms. I found an optimal time window within the ventilatory cycle in which therapy reduces ventilation oscillations by more than 95%. Outside this window therapy increases ventilatory oscillations by more than 30%. A quadratic grading of CO2 dose (combined gradation of both concentration and duration) increased treatment efficiency. The undesired increase in mean CO2 caused by dynamic therapy was negligible compared with static therapy, to achieve the same degree of ventilatory stabilisation. Similarly, the increase in average ventilation was much smaller with dynamic than static therapy. In collaboration with my clinical and engineering colleagues we tested my model findings on seven healthy subjects simulating voluntary PB and seven heart failure (HF) patients with day time spontaneous PB. Dynamic CO2 administered at hyperventilation phase achieved the greatest reduction in ETCO2 oscillations caused by voluntary PB, and practically abolished spontaneous PB in the HF patients. During dynamic CO2 administration the mean ETCO2 and ventilation levels were not different to baseline and much lower than during continuous CO2 administration, in both groups of subjects. I developed the model further to investigate the effect of random physiological fluctuations on dynamic CO2 therapy and investigated, which is the best single parameter to guide dynamic CO2 therapy. I found that if alveolar CO2 could be measured to guide therapy, it would be as effective as using ventilation. However ETCO2, the clinically observable variable, is less effective because during severe hypopnoea it markedly diverges from alveolar CO2. Dynamic CO2 therapy ameliorated both sustained PB in unstable systems and intermittent PB in stable systems, although both guidance methods became less effective with a large noise component, regardless of the underlying system stability. I investigated further the emergence of intermittent ventilatory periodic patterns, on normally stable systems (loop gain < 1), following the introduction of random physiological fluctuations into the model. This was due to the amplification of the added noise by the delay feedback system, at its natural frequency. The development of this intermittent periodic breathing pattern is dependent on the proximity of the feedback system's loop gain to its tipping point (loop gain=1.0). To investigate the possibility of modulating heart rate by using implantable pacemaker in HF patients with PB, as a tool to manipulate ETCO2 and subsequently ventilation, I devised a novel analytical model equation that demonstrated how a change in cardiac output alters alveolar CO2. We implemented this model equation and found that ETCO2 and ventilation developed consistent oscillations with period 60s during the heart rate alternations. Furthermore, we verified the mathematical prediction that the amplitude of these oscillations would depend on those in cardiac output.
Books on the topic "Chronic heart and renal failures"
1
S, Slaughter Mark, ed. Cardiac surgery in chronic renal failure. Malden, Mass: Blackwell Futura, 2007.
Find full text
2
S, Slaughter Mark, ed. Cardiac surgery in chronic renal failure. Malden, Mass: Blackwell Futura, 2007.
Find full text
3
S, Slaughter Mark, ed. Cardiac surgery in chronic renal failure. Malden, Mass: Blackwell Futura, 2007.
Find full text
4
V, Wizemann, Kramer W, and Schütterle G, eds. The heart in end-stage renal failure: Etiology, symptoms, and management of uremic heart disease. Basel: Karger, 1986.
Find full text
5
S, Parfrey Patrick, and Harnett John D, eds. Cardiac dysfunction in chronic uremia. Boston: Kluwer Academic Publishers, 1992.
Find full text
6
Keenan, Emma W. Kidney patients' wellness diet--tasty recipes: Low protein, low potassium, low sodium, and low fat diet : combined renal and triglyceride diet. Virginia Beach, Va: Grunwald and Radcliff, 1986.
Find full text
7
Slaughter, Mark S. Cardiac Surgery in Chronic Renal Failure. Wiley & Sons, Incorporated, John, 2008.
Find full text
8
Slaughter, Mark S. Cardiac Surgery in Chronic Renal Failure. Wiley & Sons, Incorporated, John, 2008.
Find full text
9
Slaughter, Mark S. Cardiac Surgery in Chronic Renal Failure. Wiley & Sons, Limited, John, 2007.
Find full text
10
Bakris, George L. Kidney in Heart Failure. Springer London, Limited, 2012.
Find full textBook chapters on the topic "Chronic heart and renal failures"
1
Böhm, Michael, Sebastian Ewen, Ina Zivanovic, and Felix Mahfoud. "Renal Denervation for Chronic Heart Failure." In Updates in Hypertension and Cardiovascular Protection, 281–92. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-34141-5_18.
Full text
2
Rascher, W., and M. Bald. "Atrial Natriuretic Peptide and Chronic Renal Failure." In Endocrinology of the Heart, 112–17. Berlin, Heidelberg: Springer Berlin Heidelberg, 1989. http://dx.doi.org/10.1007/978-3-642-83858-3_14.
Full text
3
Slaughter, Mark S. "Surgical Treatment of Valvular Heart Disease in End-Stage Renal Failure." In Cardiac Surgery in Chronic Renal Failure, 75–82. Oxford, UK: Blackwell Publishing Ltd, 2007. http://dx.doi.org/10.1002/9780470994931.ch5.
Full text
4
Kulick, D. L., and U. Elkayam. "Central and Renal Hemodynamic Effects of Diltiazem in Chronic Heart Failure." In Heart Failure Mechanisms and Management, 306–12. Berlin, Heidelberg: Springer Berlin Heidelberg, 1991. http://dx.doi.org/10.1007/978-3-642-58231-8_32.
Full text
5
Rostand, Stephen G., and Edwin A. Rutsky. "Ischemic Heart Disease in Chronic Renal Failure: Demography, Epidemiology, and Pathogenesis." In Cardiac Dysfunction in Chronic Uremia, 53–66. Boston, MA: Springer US, 1992. http://dx.doi.org/10.1007/978-1-4615-3902-5_4.
Full text
6
Damman, Kevin. "A Patient with Progressive Renal Insufficiency in Chronic Heart Failure with Reduced Ejection Fraction." In Cardiorenal Syndrome in Heart Failure, 75–87. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-21033-5_6.
Full text
7
Müller-Wieland, D., J. Brandts, M. Verket, N. Marx, and K. Schütt. "Glycaemic Control in Diabetes." In Prevention and Treatment of Atherosclerosis, 47–71. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/164_2021_537.
Full textAbstract:
AbstractReduction of glucose is the hallmark of diabetes therapy proven to reduce micro- and macro-vascular risk in patients with type 1 diabetes. However glucose-lowering efficacy trials in type 2 diabetes didn’t show major cardiovascular benefit. Then, a paradigm change in the treatment of patients with type 2 diabetes has emerged due to the introduction of new blood glucose-lowering agents. Cardiovascular endpoint studies have proven HbA1c-independent cardioprotective effects for GLP-1 receptor agonists and SGLT-2 inhibitors. Furthermore, SGLT-2 inhibitors reduce the risk for heart failure and chronic kidney disease. Mechanisms for these blood glucose independent drug target-related effects are still an enigma. Recent research has shown that GLP-1 receptor agonists might have anti-inflammatory and plaque stabilising effects whereas SGLT-2 inhibitors primarily reduce pre- and after-load of the heart and increase work load efficiency of the heart. In addition, reduction of intraglomerular pressure, improved energy supply chains and water regulation appear to be major mechanisms for renoprotection by SGLT-2 inhibitors. These studies and observations have led to recent changes in clinical recommendations and treatment guidelines for type 2 diabetes. In patients with high or very high cardio-renal risk, SGLT-2 inhibitors or GLP-1 receptor agonists have a preferred recommendation independent of baseline HbA1c levels due to cardioprotection. In patients with chronic heart failure, chronic kidney disease or at respective risks SGLT-2 inhibitors are the preferred choice. Therefore, the treatment paradigm of glucose control in diabetes has changed towards using diabetes drugs with evidence-based organ protection improving clinical prognosis.
8
Levin, Adeera. "When does anemia impact the heart in chronic kidney disease?" In Renal Anemia, 37–47. Dordrecht: Springer Netherlands, 2002. http://dx.doi.org/10.1007/978-94-015-9998-6_5.
Full text
9
Serai, Suraj D., and Meng Yin. "MR Elastography of the Abdomen: Basic Concepts." In Methods in Molecular Biology, 301–23. New York, NY: Springer US, 2021. http://dx.doi.org/10.1007/978-1-0716-0978-1_18.
Full textAbstract:
AbstractMagnetic resonance elastography (MRE) is an emerging imaging modality that maps the elastic properties of tissue such as the shear modulus. It allows for noninvasive assessment of stiffness, which is a surrogate for fibrosis. MRE has been shown to accurately distinguish absent or low stage fibrosis from high stage fibrosis, primarily in the liver. Like other elasticity imaging modalities, it follows the general steps of elastography: (1) apply a known cyclic mechanical vibration to the tissue; (2) measure the internal tissue displacements caused by the mechanical wave using magnetic resonance phase encoding method; and (3) infer the mechanical properties from the measured mechanical response (displacement), by generating a simplified displacement map. The generated map is called an elastogram.While the key interest of MRE has traditionally been in its application to liver, where in humans it is FDA approved and commercially available for clinical use to noninvasively assess degree of fibrosis, this is an area of active research and there are novel upcoming applications in brain, kidney, pancreas, spleen, heart, lungs, and so on. A detailed review of all the efforts is beyond the scope of this chapter, but a few specific examples are provided. Recent application of MRE for noninvasive evaluation of renal fibrosis has great potential for noninvasive assessment in patients with chronic kidney diseases. Development and applications of MRE in preclinical models is necessary primarily to validate the measurement against “gold-standard” invasive methods, to better understand physiology and pathophysiology, and to evaluate novel interventions. Application of MRE acquisitions in preclinical settings involves challenges in terms of available hardware, logistics, and data acquisition. This chapter will introduce the concepts of MRE and provide some illustrative applications.This publication is based upon work from the COST Action PARENCHIMA, a community-driven network funded by the European Cooperation in Science and Technology (COST) program of the European Union, which aims to improve the reproducibility and standardization of renal MRI biomarkers. This introduction chapter is complemented by another separate chapter describing the experimental protocol and data analysis.
10
House, Andrew A., Claudio Ronco, and Charles A. Herzog. "Chronic Kidney Disease and Heart Failure – A Nephrologic Approach." In Chronic Renal Disease, 560–70. Elsevier, 2015. http://dx.doi.org/10.1016/b978-0-12-411602-3.00046-9.
Full textConference papers on the topic "Chronic heart and renal failures"
1
Janssen, Daisy J. A., Martijn A. Spruit, Jos M. G. A. Schols, and Emiel F. M. Wouters. "Advance Care Planning In Patients With COPD, Chronic Heart Failure Or Chronic Renal Failure." In American Thoracic Society 2010 International Conference, May 14-19, 2010 • New Orleans. American Thoracic Society, 2010. http://dx.doi.org/10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a4015.
Full text
2
Tran, Vinh Phuc, and Adel Ali Al-Jumaily. "Non-contact real-time estimation of intrapulmonary pressure and tidal volume for chronic heart failure patients." In 2016 38th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC). IEEE, 2016. http://dx.doi.org/10.1109/embc.2016.7591498.
Full text
3
Aranki, Daniel, Gregorij Kurillo, Posu Yan, David Liebovitz, and Ruzena Bajcsy. "Continuous, Real-Time, Tele-monitoring of Patients with Chronic Heart-Failure - Lessons Learned From a Pilot Study." In 9th International Conference on Body Area Networks. ICST, 2014. http://dx.doi.org/10.4108/icst.bodynets.2014.257036.
Full text